Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Aspirin study #9 of 13   All Outcomes
6/8 Late treatment study
Horby et al., medRxiv, doi:10.1101/2021.06.08.21258132 (Preprint)
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Source   PDF   Share   Tweet
RCT 14,892 very late stage (9 days from symptom onset) hospitalized patients, not showing a significant difference in mortality with treatment. A statistically significant increased chance of hospital discharge was found for treatment <= 7 days from symptom onset (supplement page 52). Only 7% of patients were not receiving thromboprophylaxis. Authors note that the lack of benefit seen may be because there was no significant additional benefit given the high rates of antithrombotic therapy with LMWH. Authors also note that potential benefit may depend on treatment delay, especially if thrombi had developed before admission. Lower RR is shown for patients not on LMWH (0.83), and patients treated <= 7 days from onset (0.93). Results restricted to earlier treatment times are not provided. Patients already receiving aspirin were excluded. NCT04381936.
Horby et al., 6/8/2021, Randomized Controlled Trial, United Kingdom, Europe, preprint, 35 authors.
risk of death, 4.0% lower, RR 0.96, p = 0.35, treatment 1222 of 7351 (16.6%), control 1299 of 7541 (17.2%).
risk of death, 17.0% lower, RR 0.83, p = 0.11, treatment 129 of 466 (27.7%), control 169 of 513 (32.9%), no LMWH, supplement page 54.
risk of death, 7.0% lower, RR 0.93, p = 0.25, treatment 1222 of 7351 (16.6%), control 1299 of 7541 (17.2%), <=7 days from onset, supplement page 52.
risk of mechanical ventilation, 5.0% lower, RR 0.95, p = 0.32, treatment 772 of 6993 (11.0%), control 829 of 7169 (11.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 13 studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit